Commit Biologics - About the company
Commit Biologics is a seed company based in Aarhus (Denmark), founded in 2021 by Heidi Gytz Olesen, Dennis Pedersen and Mikael Winkler. It operates as a Developer of immunotherapies for the treatment of a variety of cancers. Commit Biologics has raised $23M in funding. The company has 3490 active competitors, including 1152 funded and 812 that have exited. Its top competitors include companies like BeiGene, Jazz Pharmaceuticals and Kite Pharma.
Company Details
Developer of immunotherapies for the treatment of a variety of cancers. The company combines expertise in antibody development and complement research to refine the BiCE technology and creates a new type of immunotherapy for the treatment of a variety of cancers.
- Website
- commitbio.com
- Email ID
- *****@commitbio.com
Key Metrics
Founded Year
2021
Location
Aarhus, Denmark
Stage
Seed
Total Funding
$23M in 2 rounds
Latest Funding Round
Ranked
434th among 3490 active competitors
Employee Count
33 as on Sep 30, 2026
Legal entities associated with Commit Biologics
Commit Biologics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
COMMIT BIOLOGICS APS CIN: 42642649 , Denmark, Active | - | - |
Sign up to download Commit Biologics' company profile
Commit Biologics's funding and investors
Commit Biologics has raised a total funding of $23M over 2 rounds. Its first funding round was on May 09, 2024. Its latest funding round was a Seed round on Jan 28, 2025 for $*****. 1 investor participated in its latest round. Commit Biologics has 4 institutional investors.
Here is the list of recent funding rounds of Commit Biologics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 28, 2025 | 5172820 | Seed | 8461432 | 6275863 | 3843070 | 2000260 |
May 09, 2024 | 1289525 | Seed | 4581268 | 2765213 | 6118726 |
Access funding benchmarks and valuations. Sign up today!View details of Commit Biologics's funding rounds and investors
Commit Biologics' founders and board of directors
Founder? Claim ProfileHere are the details of Commit Biologics' key team members:
- Heidi Gytz Olesen: Co-Founder of Commit Biologics. Contact Info: 1 email address
- Dennis Pedersen: Co-Founder of Commit Biologics. Contact Info: 1 email address
- Mikael Winkler: Co-Founder of Commit Biologics.
View details of Commit Biologics's Founder profiles and Board Members
Commit Biologics' employee count trend
Commit Biologics has 33 employees as of Sep 26. Here is Commit Biologics's employee count trend over the years:
Uncover Commit Biologics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Commit Biologics's Competitors and alternates
Top competitors of Commit Biologics include BeiGene, Jazz Pharmaceuticals and Kite Pharma. Here is the list of Top 10 competitors of Commit Biologics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th |  Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 72/100 | |
5th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
434th | Commit Biologics 2021, Aarhus (Denmark), Seed | Developer of immunotherapies for the treatment of a variety of cancers | $23M | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Commit Biologics's competitors? Click here to see the top ones
Commit Biologics's Investments and acquisitions
Commit Biologics has made no investments or acquisitions yet.
Reports related to Commit Biologics
Here is the latest report on Commit Biologics's sector:
News related to Commit Biologics
Filter this listMedia has covered Commit Biologics for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about people movement.
•
Commit Biologics Appoints Dr. Thomas L.F. Andresen As CEOStartup Rise EU•Mar 13, 2026•Commit Biologics
•
Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primatesPR Newswire•Nov 11, 2025•Commit Biologics
•
Commit Biologics Raises €5.5M in Seed Financing ExtensionFinSMEs•Jan 28, 2025•Commit Biologics, Korys, Novo Holdings, Bioqube Ventures
•
Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of DirectorsPR Newswire•Jan 08, 2025•Commit Biologics
•
Commit Biologics Appoints Mikkel Wandahl Pedersen As Chief Scientific OfficerPR Newswire•Oct 15, 2024•Commit Biologics
•
Commit Biologics appoints new chief scientific officerEuropean Pharmaceutical Manufacturer•Oct 15, 2024•Commit Biologics
•
Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement TherapeuticsPR Newswire•Jun 10, 2024•Commit Biologics
•
Commit Biologics: €16 Million Raised To Build Systems For Treating Cancer And Autoimmune DiseasesPulse 2.0•May 17, 2024•Commit Biologics, Bioqube Ventures, Novo Holdings
•
Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune diseasePR Newswire•May 09, 2024•Commit Biologics, Bioqube Ventures, Novo Holdings
•
Commit Biologics advances complement platform with €16m seed financingBioPharma-Reporter•May 09, 2024•Commit Biologics, Bioqube Ventures, Novo Holdings
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Commit Biologics
Explore our recently published companies
- The Virtual Ocean - India based, 2021 founded, Unfunded company
- EmployaLingua - Manchester based, Unfunded company
- Emerald ATM - Sherman Oaks based, 2013 founded, Unfunded company
- Rivra ERP - Unfunded company
- Elland Computers & Mobiles - United Kingdom based, 2016 founded, Unfunded company
- El Rumbo de New York - New York based, 1970 founded, Unfunded company
